Global Angina Pectoris Drugs Market size and share is currently valued at USD 11.76 billion in 2024 and is anticipated to generate an estimated revenue of USD 17.25 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 3.9% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034
Key Market Growth Drivers
Rising Cardiovascular Disease Burden: CVDs continue to be the leading cause of mortality worldwide. The World Health Organization reports that ischemic heart disease accounts for 16% of all deaths globally. The increasing prevalence of such conditions underscores the demand for effective angina pectoris treatments.
Advancements in Drug Formulations: Innovations in drug delivery systems, including extended-release formulations of nitrates and beta-blockers, have improved patient compliance and therapeutic outcomes. These advancements reduce dosing frequency and maintain stable drug levels, enhancing the overall efficacy of angina management.
Emphasis on Personalized Medicine: The healthcare industry's shift towards personalized medicine allows for tailored treatment strategies based on individual patient profiles. This approach enhances treatment effectiveness and minimizes adverse effects, fostering better patient outcomes in angina pectoris management.
Expanding Healthcare Infrastructure: Developing regions are witnessing improvements in healthcare infrastructure, increasing access to medical services and angina treatments. This expansion facilitates early diagnosis and intervention, contributing to market growth.
Key Companies
- Pfizer Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Novartis AG
- Merck Co., Inc.
- Sanofi S.A.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Johnson Johnson
- Roche Holding AG
- Boehringer Ingelheim GmbH
- Abbott Laboratories
- Amgen Inc.
- Bayer AG
- Takeda Pharmaceutical Company Limited
Market Challenges
Despite the positive outlook, the market faces certain challenges:
Side Effects of Medications: Some angina medications, such as nitrates and beta-blockers, may cause side effects like hypotension, bradycardia, and fatigue, potentially affecting patient adherence.
Preference for Surgical Interventions: In cases of severe angina, patients may opt for surgical procedures like angioplasty or bypass surgery over long-term pharmacological management, impacting drug market growth.
Regulatory Hurdles: The stringent regulatory landscape for drug approvals can delay the introduction of new therapies, affecting market dynamics.
Market Segmentation
By Type:
Stable Angina: This segment dominated the market with a 52.2% revenue share in 2023. Stable angina, often triggered by physical exertion or stress, is the most common form and is typically managed with medications and lifestyle modifications.
Unstable Angina: Characterized by unexpected chest pain, unstable angina requires immediate medical attention. This segment is expected to witness the fastest growth due to its severity and the need for prompt treatment.
By Drug Class:
Beta Blockers: Holding a 38.8% market share in 2023, beta blockers are first-line therapies that reduce heart rate and myocardial oxygen demand, effectively managing angina symptoms.
Anticoagulants: These drugs prevent blood clots, reducing the risk of heart attacks in angina patients. The introduction of novel oral anticoagulants (NOACs) has enhanced treatment options.
Nitrates: Used for immediate relief of angina attacks, nitrates dilate blood vessels, improving blood flow to the heart.
Calcium Channel Blockers: These medications relax blood vessels and reduce heart workload, aiding in angina management.
By Route of Administration:
Oral: Oral medications are preferred for their convenience and cost-effectiveness, especially for long-term management.
Parenteral: Intravenous drugs are used in acute settings for rapid symptom relief.
Transdermal: Patches provide a steady release of medication, beneficial for patients requiring consistent dosing.
By Distribution Channel:
Hospital Pharmacies: Accounting for 48.5% of the market share in 2023, hospital pharmacies are primary sources for angina medications, especially for inpatients.
Retail Pharmacies: These outlets cater to outpatients and those managing chronic angina.
Online Pharmacies: With the rise of digital health, online pharmacies are gaining popularity, offering convenience and broader access to medications.
Regional Analysis
North America: Leading the global market with over 40% revenue share in 2023, North America's dominance is attributed to advanced healthcare infrastructure, high prevalence of CVDs, and significant investments in research and development.
Europe: Countries like Germany, the UK, and France contribute significantly to the market, driven by robust healthcare systems and increasing awareness of heart health.
Asia Pacific: Expected to be the fastest-growing region with a CAGR of 5.5%, growth is fueled by rising CVD cases, improving healthcare facilities, and increasing health awareness in countries like China and India.
Latin America and Middle East Africa: These regions are witnessing gradual growth due to improving healthcare access and rising prevalence of lifestyle-related diseases.
Explore More:
https://www.polarismarketresearch.com/industry-analysis/angina-pectoris-drugs-market
Future Outlook
The angina pectoris drugs market is set for steady growth, propelled by the increasing burden of cardiovascular diseases, advancements in drug development, and expanding healthcare access. Emphasis on personalized medicine and innovative drug delivery systems will further enhance treatment efficacy and patient adherence. However, addressing challenges such as medication side effects and regulatory hurdles will be crucial for sustained market expansion.
Hemodialysis and Peritoneal Dialysis Market
India Diagnostic Services Market
Medical Device Outsourcing Market
Irritable Bowel Syndrome (IBS) Treatment Market
Nephrology and Urology Devices Market
Medical Waste Container Market
Non-Invasive Prenatal Testing (NIPT) Market
